Startup Developing Diagnostic Device To Monitor Hemostatis Raises $1.3 Million

 A Virginia startup that has developed a point-of-care diagnostic device to monitor and characterize the progress of hemostasis has raised $1.23 million, according to a regulatory filing. 

HemoSonics has developed a proprietary technology called sonorheometry, which is an ultrasound-based technique for the "non-contact assessment of mechanical properties of soft tissues." These allow clinicians to know how hemostasis and the consequent dissolution of the blood clot are progressing.

The formation of a blood clot and its ultimate dissolution is necessary in various clinical settings and hemostatic disorders can result in heart attack, stroke, pulmonary embolism, excessive bleeding, and other conditions, according to HemoSonics's website.

That has led the company to develop a diagnostic device with disposable cartridges that comes preloaded with the reagents needed to monitor and characterize hemostasis. 

William Falker is the president of HemoSonics and his bio lists experience in founding several ultrasound-based device companies. 

By Arundhati Parmar, Senior Editor, MD+DI